Seer Inc at Morgan Stanley Global Healthcare Conference Transcript
Hello, everyone. Good morning. I'm Tejas Savant and I cover the Life Science Tools and Diagnostics sector here at Morgan Stanley. Before we begin, important disclosures. Please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, do reach out to your sales rep.
So it's my pleasure this morning to host here. And on behalf of the company, we have Omid Farokhzad CEO; and David Horn, CFO. So thanks, gents, for spending the next 30 minutes with me. Omid, I want to start at a high level, right? So despite some of the near-term headwinds, which we get to later in the chat, I want to talk to you about sort of what's gone right over the last 12 months for SEER? At an industry level, the excitement around multiomic in general and proteomic specifically is tappable. What are you most proud of in terms of what you've accomplished since IPO?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |